Articles tagged with Vaccine Research
A new study by ESMT Berlin finds that fractional-dose vaccines can significantly reduce infections during epidemics, especially in low-resource settings. The researchers identify vaccination policies that minimize infections while accounting for limited stockpiles and administration capacity.
Researchers tested a 'mental model' approach to counter unwarranted fears about mRNA technology. The study found that exposing people to visual models of how vaccines work and/or how cells protect DNA from foreign fragments undercuts the effect of exposure to misconceptions.
Two new Cochrane reviews show that HPV vaccines are effective in preventing cervical cancer and pre-cancerous changes, especially when given to young people before they are exposed to the virus. Girls vaccinated before the age of 16 were found to be 80% less likely to develop cervical cancer.
Scientists have developed a fast-acting and long-lasting vaccine against Crimean-Congo hemorrhagic fever (CCHF), which is one of the world's most dangerous infectious diseases. The vaccine, made from a virus-like replicon particle, provides durable humoral immunity for up to 18 months.
A new approach developed by University of Waterloo researchers uses social media posts to identify early warning signs of increasing vaccine skepticism. This method can detect patterns in data much more effectively than traditional methods, providing a bigger lead time before an outbreak occurs.
The partnership aims to co-develop and evaluate next-generation self-amplifying RNA (saRNA) vaccines targeting seasonal and pandemic influenza. Apriori's Octavia platform will be combined with A*STAR IDL's saRNA delivery technology to develop improved H5 influenza vaccines that anticipate infection in humans.
This book explores the evolution of patent protection in vaccinology and its impact on vaccine distribution and research collaboration. It highlights the need for balanced IP systems to encourage scientific progress while ensuring public health equity.
A comprehensive review of over 25 years of research on non-specific vaccine effects reveals no evidence to support the claim that vaccines protect against diseases other than the ones they are designed to prevent. The study, which analyzed 13 randomized trials, shows that prominent researchers have systematically over-interpreted the f...
Leading experts urge universal hepatitis B vaccination for all newborns in the US, citing a 95% decline in infant infections since 1991. The policy has prevented an estimated one million hospitalizations and 90,000 deaths.
The Vaccine Innovation Center at Korea University College of Medicine has been selected as the lead institution for a health security research initiative focused on developing broad-spectrum antiviral agents and combination therapies to prevent severe disease in future pandemics. The project aims to create advanced therapeutics capable...
The Phase 3 study demonstrated the safety and non-inferiority of EuTYPH-C Inj.® Multi-dose compared to a World Health Organization (WHO) prequalified comparator TCV, Typbar TCV®. The vaccine was shown to be well-tolerated across all age groups with no serious adverse events.
Researchers at the University of Pittsburgh have developed a skin patch test that can detect antibodies associated with COVID and flu infections. The test uses carbon nanotubes and is orders of magnitude more sensitive than existing tests.
A new nasally-delivered vaccine has been shown to prevent severe disease and curb bacterial transmission, addressing a global need for next-generation immunisation technologies. The vaccine targets the respiratory mucosa, providing stronger protection against respiratory infections.
Researchers have developed particles that can deliver an effective immune response at a much lower dose than traditional mRNA vaccines. The new particles, called AMG1541, use cyclic structures and ester groups to enhance mRNA delivery and improve biodegradability. This could potentially reduce vaccine costs and side effects.
Researchers at MIT have identified possible antigens for a new TB vaccine, stimulating a strong immune response in T cells. The study reveals 27 TB peptides that appear most often on infected cell surfaces and elicit a T cell response in at least some samples.
Researchers have discovered that human astroviruses bind to a protein in human cells called the neonatal Fc receptor. The study provides a key target for vaccine development and repurposing of existing treatments.
A new analytical tool using Raman spectroscopy enables rapid monitoring of vaccine quality and quantity, with results in 30 seconds or less. The tool operates on the production line, saving time and money in vaccine production.
Scientists have characterized lipid nanoparticles' internal shape and structure, which correlates with how well they deliver therapeutic cargo. The research provides a blueprint for engineering more effective RNA therapies by matching LNP designs to specific therapies and tissues.
Patients with advanced lung and skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer. The vaccine was associated with a near doubling of median survival, from 20.6 months to 37.3 months in lung cancer patients.
The recombinant shingles vaccine achieved over 50% effectiveness against any herpes zoster outcome in both older and immunocompromised adults. The study suggests individuals previously vaccinated with live zoster should be revaccinated with two doses of RZV to maintain protection.
Researchers have developed a new mRNA vaccine technology using albumin-recruiting lipid nanoparticles to deliver vaccines precisely to lymph nodes, avoiding liver toxicity. The approach outperformed traditional delivery systems in laboratory tests, producing strong antitumor T-cell responses and high levels of neutralizing antibodies.
A Phase 1 clinical trial has successfully tested a new vaccine against typhoid fever and invasive non-typhoidal Salmonella, demonstrating strong immune responses in healthy adults. The vaccine triggered balanced immune defenses and showed potential for whole-body protection against Salmonella.
The Qdenga vaccine provided a 50% reduction in symptomatic dengue cases and 68% hospitalization rate after one dose, with protection lasting three months. The study's findings have significant implications for public health decision-making, particularly in non-endemic regions where local transmission is increasing.
A new Cochrane review finds RSV vaccines reduce the risk of infection in vulnerable groups, including older adults and infants. Vaccination also significantly reduces severe disease and hospitalization rates.
Researchers developed an mRNA vaccine that suppresses abnormal blood vessel growth in mouse models of age-related macular degeneration. The vaccine is as effective as current therapies and offers a convenient alternative to frequent eye injections.
A meta-analysis of over 1.2 million pregnant individuals found COVID-19 vaccination reduced maternal infection rates and stillbirth risk. Vaccination also lowered risk of preterm birth and congenital anomalies.
The VCU Massey Comprehensive Cancer Center, along with 61 other NCI-Designated Cancer Centers, has endorsed a joint statement urging healthcare systems and the public to prioritize HPV vaccination for cancer prevention. HPV vaccination is safe and effective in preventing six types of cancers caused by HPV infection.
Australian scientists have discovered how T follicular helper cells tailor their behavior to different infections, paving the way for improved vaccine design and targeted therapies. The study sheds light on a molecular 'instruction manual' guiding antibody production and long-term immunity.
The University of California - Riverside is receiving a $2 million grant to investigate how gut microbes interact with their human hosts to influence health. The research aims to create next-generation probiotics that strengthen the gut microbiome, improve vaccine effectiveness, and prevent infections.
Scientists found that stretching the skin stimulates immune cells and increases its ability to absorb large molecules, including vaccines. This approach resulted in higher antibody levels against the H1N1 flu antigen compared to traditional needle-free delivery methods.
A chemically modified STn glycoconjugate vaccine has been developed with enhanced antitumor immunity, demonstrating substantial resistance to enzymatic degradation and inducing potent T-cell responses. The vaccine induces functional antibodies capable of initiating both CDC and ADCC against STn-positive tumor cells.
Research with human fetal tissue has been instrumental in advancing biomedicine and saving millions of lives. The ISSCR asserts that this work is essential for understanding human development, infertility, and diseases like diabetes and neurodegenerative disorders.
A new project aims to increase HPV vaccine uptake by harnessing AI to tailor health information to parents' specific concerns and communication styles. The AI-driven chatbot will simulate human conversation, addressing misconceptions and fears associated with the vaccine.
A comprehensive registry study in Sweden found that healthy, full-term babies under three months old are at risk of severe illness from RSV. The study highlights several risk factors, including birth weight and sibling age, which increase the risk of needing intensive care or dying.
Stefan Kappe, a leading expert in genetic engineering of parasites, has been appointed as the new Director of the Center for Vaccine Development and Global Health at UM School of Medicine. He will focus on developing genetically engineered live-attenuated pathogens to combat malaria infection.
Researchers developed a high-volume method to rapidly build and test large numbers of antibodies at once, accelerating antibody research and treatment development. The oPool+ display platform has potential applications in influenza vaccination research, infectious disease treatment, and cancer research.
Researchers at Texas Biomed have developed a live attenuated vaccine that showed high efficacy in cells and animal models, protecting mice from lethal H5N1. The team identified potential treatment targets using human airway organoids, revealing how bird flu remodels airway cells and causes scar tissue to form.
A new vaccine developed to protect against 21 strains of pneumococcus will be tested in a randomised controlled trial, aiming to provide greater protection for babies against serious infections. The trial is recruiting over 1600 babies across Australia and internationally.
Researchers found that HPV16 undermines the body's defenses by reprogramming immune cells surrounding tumors. Blocking IL-23 boosts experimental treatments for HPV to eliminate cancer cells.
Researchers discovered that vaccines induce changes in stromal cells of draining lymph nodes within hours, priming the landscape for immune responses. Different vaccines activate lymph node stromal cells differently, with some inducing specific effects on lymphatic endothelial cells.
MIT researchers have developed a method to reveal the inner workings of protein language models, which can accurately predict proteins suitable for drug or vaccine targets. By analyzing sparse representations of proteins, they identified key features that drive these predictions.
A new study finds reported conflicts of interest on CDC vaccine panels had been at historic lows for years before Kennedy's dismissal. The type of conflict typically considered most concerning, income from vaccine makers, was virtually eliminated among panel members.
Researchers used machine-learning models to design nanoparticles that can deliver RNA to cells more efficiently. The approach accelerated the identification of optimal ingredient mixtures in lipid nanoparticles, leading to better delivery vehicles for RNA vaccines and mRNA therapies. This could dramatically speed up the development of ...
A recent study reveals woefully low awareness of human papillomavirus (HPV), the HPV vaccine, and their association with cancer in the Midwestern and Southern US states. These states have seen a rise in HPV-associated cancers, making suboptimal HPV vaccination rates even more alarming.
New research reveals that most people are unaware of the link between human papillomavirus (HPV) and various types of cancer, including cervical, oropharyngeal, anal, vaginal, vulvar, and penile cancers. The study highlights the importance of HPV vaccination in preventing these cancers.
A comprehensive epidemiological study found that people who had COVID-19 are at increased risk of developing certain inflammatory diseases of the airways, such as asthma and chronic sinusitis. Vaccination against SARS-CoV-2 virus appears to reduce this risk.
A novel cancer vaccine has shown encouraging early results in patients with pancreatic and colorectal cancer, two of the most difficult-to-treat malignancies. The vaccine targets KRAS mutations found in about 25% of solid tumors and drives about 90% of pancreatic cancers and 50% of colorectal cancers.
This book delves into the scientific foundations of mucosal vaccine platforms, discussing immunological mechanisms, novel adjuvants, and real-world development challenges. It serves as a valuable resource for professionals and students in life sciences, immunology, and pharmacology.
Key findings show a decline in childhood and adolescent immunization rates in Michigan, with completion rates dropping sharply during the COVID-19 pandemic. The study highlights the need for targeted efforts to increase immunization rates in counties with lower income and higher uninsurance rates.
A multi-year clinical research study in US children documents the rebound of endemic respiratory viruses after the COVID-19 pandemic. The study shows that non-pharmaceutical interventions decreased circulation rates of common respiratory pathogens in children, enabling more accurate predictions for future outbreaks.
Researchers at CUNY ASRC discover that simple tripeptides can encapsulate proteins and protect them from stress, opening up possibilities for protein preservation without refrigeration. This breakthrough could lead to innovative vaccine distribution methods and smart materials.
The study found that the vaccine effectively induces a rapid mucosal and systemic IgA response, but its protective effect against emerging variants like JN.1 appears short-lived. The results highlight the need for improved mucosal vaccine platforms capable of inducing durable immunity.
Researchers have demonstrated a novel vaccine delivery method using dental floss, which stimulates the production of antibodies in mucosal surfaces, such as the lining of the nose and lungs. This technique has shown superior antibody response compared to current oral vaccination methods.
Researchers at Nagoya University have developed a new lipid nanoparticle that delivers mRNA five times more efficiently, allowing better delivery of genetic instructions to cells. The study showed significant improvements in mRNA delivery and effective suppression of tumor growth in mice.
Researchers developed an IBDV VP2 subunit vaccine that induces specific antibodies and protects against bursal atrophy. The study found that using certain adjuvants, such as Montanide ISA 78 VG, enhances the protective effects of the vaccine.
A genetic study in mice reveals that TB bacteria can survive in vaccinated or previously infected hosts by switching strategies and relying on different genes. The research could lead to the creation of treatments given alongside vaccines to help the immune system root out TB when it tries to hide.
A novel formulation and delivery approach for the NeoVax personalized cancer vaccine improved immune responses in patients with melanoma. The updated vaccine demonstrated strong vaccine-specific immune responses and cytotoxic responses by special T cells called CD-8+ T cells.
Djenet Bousbaine's research explores how the immune system responds to beneficial skin microbes, triggering wound-healing T cells and robust B cell responses. This phenomenon is observed in humans, non-human primates, and found to be evolutionary conserved.
Renowned vaccine expert Pierre Van Damme shared his experience leading over 500 clinical trials and establishing Vaccinopolis, a global research hub for vaccine clinical trials. The Vaccine Innovation Center of Korea University's College of Medicine aims to expand global cooperation in vaccine R&D through special seminars.
Researchers at MIT and Scripps Research Institute developed a vaccine that generates many more HIV-targeting B cells in mice with just one dose, using two adjuvants. The dual-adjuvant vaccine produces a wider diversity of antibodies against an HIV antigen, allowing the immune system to build up a stronger response.